Physician profile
Joan Campbell Leavens
NPI 1518321074
$4,344.84
in general payments reported to CMS, 2019-2025
18 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 79% of Dermatopathology (Dermatology) providers received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $125 · 2020: $125 · 2021: $236 · 2022: $452 · 2023: $713 · 2024: $1,296 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,330 · Education: $77.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,329.58 |
| Education | $77.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.93 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $549.76 | 2021-2025 | Ilumya |
| Ucb, INC. | $495.45 | 2023-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $356.90 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $319.12 | 2022-2025 | Libtayo, Dupixent |
| E.R. Squibb & Sons, L.L.C. | $272.71 | 2023-2025 | Sotyktu |
| Incyte Corporation | $224.84 | 2024-2025 | Opzelura |
| Dermavant Sciences, INC. | $182.78 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $145.17 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $140.71 | 2025 | Nemluvio, Aklief |
| Celgene Corporation | $124.83 | 2019 | |
| Leo Pharma INC. | $115.46 | 2022-2024 | Adbry |
| Janssen Biotech, INC. | $98.75 | 2023-2025 | Tremfya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.31 | 2022-2025 | Cabtreo, Siliq, Jublia |
| Organon LLC | $28.44 | 2025 | Vtama |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $22.34 | 2025 | Sofdra |
| Smith+Nephew, INC. | $18.83 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.51 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Leavens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.